Nabriva's Antibiotic Lefamulin Does Well In First Of Two Pivotal Trials

Results from the first Phase III study – LEAP 1 – of the antibiotic lefamulin are positive, and Nabriva still has one trial to go. But the firm believes that regardless of that result, the totality of data could be used to support regulatory filings.

lung illustration

With results from the first Phase III study of its antibiotic lefamulin in community-acquired bacterial pneumonia now under its belt and a second pivotal study due to report in the spring of 2018, Nabriva Therapeutics AG is gearing up for a regulatory filing in the US.

Nabriva announced Sept. 18 that in the LEAP 1 study, lefamulin met the primary endpoint of non-inferiority for early clinical...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category